Transplant Drug Linked to Birth Defects

29 Oct 2007

WASHINGTON (AP) — A drug to prevent organ rejection in transplant patients may cause birth defects, health officials warned Monday.

The drug, called CellCept, also may cause miscarriages, the Food and Drug Administration added.

The FDA also warned that taking the drug, made by Switzerland’s Roche Holding, may lower blood levels of the hormones in birth control pills, theoretically making them less effective at preventing pregnancy.

Women of childbearing potential should have a negative pregnancy test within a week of starting the immune-system suppressing drug, and must receive birth control counseling and use effective contraception, the FDA said.

Some doctors prescribe CellCept to lupus patients who cannot tolerate chemotherapy. The drug is known generically as mycophenolate mofetil.

(A friend – a transplant recipient herself, is nice enough to send me articles that she thinks we’d be interested in. And yes, I find this very interesting. And scary. Many questions are put in the “To Think About Later File” because it isn’t like we can do it without this drug.)